Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 19, 2015, Pages 7719-7733

  Weigel, Lena F ^a   Nitsche, Christoph ^a   Graf, Dominik ^a   Bartenschlager, Ralf ^a   Klein, Christian D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITRO LEVO PHENYLGLYCINE; 3 NITRO LEVO PHENYLGLYCINE METHYL ESTER HYDROCHLORIDE; 4 CYANO LEVO PHENYLALANINE METHYL ESTER HYDROCHLORIDE; ANTIVIRUS AGENT; APROTININ; N BENZOYL (3 AMINO) LEVO PHENYLALANINE METHYL ESTER HYDROCHLORIDE; N BENZOYL (3 AMINO) LEVO PHENYLGLYCINE METHYL ESTER HYDROCHLORIDE; N BENZOYL (3 AMINOMETHYL) LEVO PHENYLALANINE METHYL ESTER TRIFLUOROACETATE; N BENZOYL (3 BIS BOC GUANIDINO) LEVO PHENYLALANINE; N BENZOYL (3 BIS BOC GUANIDINO) LEVO PHENYLGLYCINE; N BENZOYL (3 BIS BOC GUANIDINO) LEVO PHENYLGLYCINE METHYL ESTER; N BENZOYL (3 CYANO) LEVO PHENYLALANINE METHYL ESTER; N BENZOYL (3 NITRO) LEVO PHENYLALANINE METHYL ESTER; N BENZOYL (3 NITRO) LEVO PHENYLGLYCINE METHYL ESTER; N BENZOYL (4 AMINO) LEVO PHENYLALANINE METHYL ESTER HYDROCHLORIDE; N BENZOYL (4 AMINOMETHYL) LEVO PHENYLALANINE METHYL ESTER; N BENZOYL (4 CYANO) LEVO PHENYLALANINE METHYL ESTER; N BENZOYL (4 CYANO) LEVO PHENYLGLYCINE; N BENZOYL (4 CYANO) LEVO PHENYLGLYCINE METHYL ESTER; PHENYLALANINE DERIVATIVE; PHENYLGLYCINE; PROTEINASE INHIBITOR; THROMBIN; UNCLASSIFIED DRUG; ARGININE; NS3 PROTEASE, DENGUE VIRUS; PHENYLALANINE; SERINE PROTEINASE;

ANTIVIRAL ACTIVITY; ARTICLE; BIOMIMETICS; BLOOD CLOTTING; CHEMICAL STRUCTURE; DENGUE VIRUS; HYDROGENATION; HYDROLYSIS; IC50; IN VITRO STUDY; INTESTINAL AVAILABILITY; MEMBRANE PERMEABILITY; METABOLIC CLEARANCE; METABOLIC STABILITY; MOLECULAR DOCKING; NITRATION; NONHUMAN; PEPTIDE SYNTHESIS; SEROTYPE; STATIC ELECTRICITY; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; DRUG STABILITY; ENZYMOLOGY; HUMAN; MALE; METABOLISM; MOLECULAR MIMICRY; PATHOGENICITY; PRECLINICAL STUDY; PROCEDURES; SPRAGUE DAWLEY RAT; SYNTHESIS; VIROLOGY; WEST NILE VIRUS;

ANIMALS; ANTIVIRAL AGENTS; APROTININ; ARGININE; CELL LINE; CELL MEMBRANE PERMEABILITY; DENGUE VIRUS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; MOLECULAR MIMICRY; PHENYLALANINE; PROTEASE INHIBITORS; RATS, SPRAGUE-DAWLEY; SERINE ENDOPEPTIDASES; STRUCTURE-ACTIVITY RELATIONSHIP; WEST NILE VIRUS;

EID: 84943749258     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00612     Document Type: Article

References (61)

1. Brady, O. J.; Gething, P. W.; Bhatt, S.; Messina, J. P.; Brownstein, J. S.; Hoen, A. G.; Moyes, C. L.; Farlow, A. W.; Scott, T. W.; Hay, S. I. Refining the global spatial limits of dengue virus transmission by evidence-based consensus PLoS Neglected Trop. Dis. 2012, 6 (8) e1760 10.1371/journal.pntd.0001760
2. Bhatt, S.; Gething, P. W.; Brady, O. J.; Messina, J. P.; Farlow, A. W.; Moyes, C. L.; Drake, J. M.; Brownstein, J. S.; Hoen, A. G.; Sankoh, O.; Myers, M. F.; George, D. B.; Jaenisch, T.; Wint, G. R. W.; Simmons, C. P.; Scott, T. W.; Farrar, J. J.; Hay, S. I. The global distribution and burden of dengue Nature 2013, 496 (7446) 504-507 10.1038/nature12060
3. Schmidt-Chanasit, J.; Haditsch, M.; Schöneberg, I.; Günther, S.; Stark, K.; Frank, C. Dengue virus infection in a traveller returning from Croatia to Germany Eurosurveillance 2010, 15 (40) 19677
4. La Ruche, G.; Souarès, Y.; Armengaud, A.; Peloux-Petiot, F.; Delaunay, P.; Desprès, P.; Lenglet, A.; Jourdain, F.; Leparc-Goffart, I.; Charlet, F. First two autochthonous dengue virus infections in metropolitan France, September 2010 Eurosurveillance 2010, 15 (39) 19676
5. Nitsche, C.; Holloway, S.; Schirmeister, T.; Klein, C. D. Biochemistry and medicinal chemistry of the dengue virus protease Chem. Rev. 2014, 114 (22) 11348-11381 10.1021/cr500233q
6. Vasilakis, N.; Ooi, M.; Rabaa, M.; Mayer, S.; Widen; Perera, D.; Hickey, A.; Travassos Da Rosa, A.; Bossart, K.; Tesh, R.; Holmes, E.; Cardos, J. The daemon in the forest-emergence of a new dengue serotype in South East Asia. In 3rd International Conference on Dengue and Dengue Haemorrhagic Fever, Bangkok, 2013.
7. Lim, S. P.; Wang, Q.-Y.; Noble, C. G.; Chen, Y.-L.; Dong, H.; Zou, B.; Yokokawa, F.; Nilar, S.; Smith, P.; Beer, D.; Lescar, J.; Shi, P.-Y. Ten years of dengue drug discovery: Progress and prospects Antiviral Res. 2013, 100 (2) 500-519 10.1016/j.antiviral.2013.09.013
8. Noble, C. G.; Shi, P.-Y. Structural biology of dengue virus enzymes: Towards rational design of therapeutics Antiviral Res. 2012, 96 (2) 115-126 10.1016/j.antiviral.2012.09.007
9. De Clercq, E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV Int. J. Antimicrob. Agents 2009, 33 (4) 307-320 10.1016/j.ijantimicag.2008.10.010
10. Wensing, A. M. J.; van Maarseveen, N. M.; Nijhuis, M. Fifteen years of HIV protease inhibitors: Raising the barrier to resistance Antiviral Res. 2010, 85 (1) 59-74 10.1016/j.antiviral.2009.10.003
11. Poordad, F.; McCone, J.; Bacon, B. R.; Bruno, S.; Manns, M. P.; Sulkowski, M. S.; Jacobson, I. M.; Reddy, K. R.; Goodman, Z. D.; Boparai, N.; DiNubile, M. J.; Sniukiene, V.; Brass, C. A.; Albrecht, J. K.; Bronowicki, J.-P. Boceprevir for untreated chronic HCV Genotype 1 infection N. Engl. J. Med. 2011, 364 (13) 1195-1206 10.1056/NEJMoa1010494
12. Zeuzem, S.; Andreone, P.; Pol, S.; Lawitz, E.; Diago, M.; Roberts, S.; Focaccia, R.; Younossi, Z.; Foster, G. R.; Horban, A.; Ferenci, P.; Nevens, F.; Müllhaupt, B.; Pockros, P.; Terg, R.; Shouval, D.; van Hoek, B.; Weiland, O.; Van Heeswijk, R.; De Meyer, S.; Luo, D.; Boogaerts, G.; Polo, R.; Picchio, G.; Beumont, M. Telaprevir for retreatment of HCV infection N. Engl. J. Med. 2011, 364 (25) 2417-2428 10.1056/NEJMoa1013086
13. Liu, H.; Wu, R.; Sun, Y.; Ye, Y.; Chen, J.; Luo, X.; Shen, X.; Liu, H. Identification of novel thiadiazoloacrylamide analogues as inhibitors of dengue-2 virus NS2B/NS3 protease Bioorg. Med. Chem. 2014, 22 (22) 6344-6352 10.1016/j.bmc.2014.09.057
14. Tomlinson, S. M.; Watowich, S. J. Anthracene-based inhibitors of dengue virus NS2B-NS3 protease Antiviral Res. 2011, 89 (2) 127-135 10.1016/j.antiviral.2010.12.006
15. Behnam, M. A. M.; Nitsche, C.; Vechi, S. M.; Klein, C. D. C-Terminal residue optimization and fragment merging: Discovery of a potent peptide-hybrid inhibitor of dengue protease ACS Med. Chem. Lett. 2014, 5 (9) 1037-1042 10.1021/ml500245v
16. Erbel, P.; Schiering, N.; D'Arcy, A.; Renatus, M.; Kroemer, M.; Lim, S. P.; Yin, Z.; Keller, T. H.; Vasudevan, S. G.; Hommel, U. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus Nat. Struct. Mol. Biol. 2006, 13 (4) 372-373 10.1038/nsmb1073
17. Yin, Z.; Patel, S. J.; Wang, W.-L.; Chan, W.-L.; Ranga Rao, K. R.; Wang, G.; Ngew, X.; Patel, V.; Beer, D.; Knox, J. E.; Ma, N. L.; Ehrhardt, C.; Lim, S. P.; Vasudevan, S. G.; Keller, T. H. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors Bioorg. Med. Chem. Lett. 2006, 16 (1) 40-43 10.1016/j.bmcl.2005.09.049
18. Nitsche, C.; Behnam, M. A. M.; Steuer, C.; Klein, C. D. Retro peptide-hybrids as selective inhibitors of the dengue virus NS2B-NS3 protease Antiviral Res. 2012, 94 (1) 72-79 10.1016/j.antiviral.2012.02.008
19. Nitsche, C.; Schreier, V. N.; Behnam, M. A. M.; Kumar, A.; Bartenschlager, R.; Klein, C. D. Thiazolidinone-peptide hybrids as dengue virus protease inhibitors with antiviral activity in cell culture J. Med. Chem. 2013, 56 (21) 8389-8403 10.1021/jm400828u
20. Bastos Lima, A.; Behnam, M. A. M.; El Sherif, Y.; Nitsche, C.; Vechi, S. M.; Klein, C. D. Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids Bioorg. Med. Chem. 2015, 23, 5748-5755 10.1016/j.bmc.2015.07.012
21. Brenner, M.; Huber, W. Herstellung von α-Aminosäureestern durch Alkoholyse der Methylester Helv. Chim. Acta 1953, 36 (5) 1109-1115 10.1002/hlca.19530360522
22. Steinmetzer, T.; Becker, G.; Garten, W. N-Terminally modified tetrapeptide derivatives having a c-terminal arginine mimetic. U.S. Patent 0,312,873, December 22, 2011.
23. Hammamy, M. Z.; Haase, C.; Hammami, M.; Hilgenfeld, R.; Steinmetzer, T. Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 Protease ChemMedChem 2013, 8 (2) 231-241 10.1002/cmdc.201200497
24. Cesar, J.; Nadrah, K.; Sollner Dolenc, M. Solid-phase synthesis of amidines by the reduction of amidoximes Tetrahedron Lett. 2004, 45 (40) 7445-7449 10.1016/j.tetlet.2004.08.055
25. Herzner, H.; Kunz, H. (p-Sulfomethyl)phenylalanine as a mimic of O-sulfatyl-tyrosine in synthetic partial sequences of P-Selectin glycoprotein ligand 1 (PSGL-1) Tetrahedron 2007, 63 (28) 6423-6436 10.1016/j.tet.2007.03.028
26. Bazewicz, C. G.; Lipkin, J. S.; Lozinak, K. A.; Watson, M. D.; Brewer, S. H. Synthesis of isotopomers of N-(tert-butoxycarbonyl)-4-cyano-l-phenylalanine methyl ester: choice of cyanation solvent Tetrahedron Lett. 2011, 52 (51) 6865-6868 10.1016/j.tetlet.2011.10.050
27. Takagi, K.; Sakakibara, Y. Nickel(0) or palladium(0)-catalyzed cyanation of aryl triflates Chem. Lett. 1989, 18 (11) 1957-1958 10.1246/cl.1989.1957
28. Chhabra, S. R.; Hothi, B.; Evans, D. J.; White, P. D.; Bycroft, B. W.; Chan, W. C. An appraisal of new variants of Dde amine protecting group for solid phase peptide synthesis Tetrahedron Lett. 1998, 39 (12) 1603-1606 10.1016/S0040-4039(97)10828-0
29. Díaz-Mochón, J. J.; Bialy, L.; Bradley, M. Full orthogonality between Dde and Fmoc: The direct Synthesis of PNA-Peptide conjugates Org. Lett. 2004, 6 (7) 1127-1129 10.1021/ol049905y
30. Chappell, K. J.; Stoermer, M. J.; Fairlie, D. P.; Young, P. R. Insights to substrate binding and processing by West Nile virus NS3 Protease through combined modeling, protease mutagenesis, and kinetic studies J. Biol. Chem. 2006, 281 (50) 38448-38458 10.1074/jbc.M607641200
31. Gouvea, I. E.; Izidoro, M. A.; Judice, W. A. S.; Cezari, M. H. S.; Caliendo, G.; Santagada, V.; dos Santos, C. N. D.; Queiroz, M. H.; Juliano, M. A.; Young, P. R.; Fairlie, D. P.; Juliano, L. Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: Influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates Arch. Biochem. Biophys. 2007, 457 (2) 187-196 10.1016/j.abb.2006.11.005
32. Schüller, A.; Yin, Z.; Brian Chia, C. S.; Doan, D. N. P.; Kim, H.-K.; Shang, L.; Loh, T. P.; Hill, J.; Vasudevan, S. G. Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease Antiviral Res. 2011, 92 (1) 96-101 10.1016/j.antiviral.2011.07.002
33. Clement, B. Reduction of N-hydroxylated compounds: Amidoximes (N-Hydroxyamidines) as Pro-Drugs of amidines Drug Metab. Rev. 2002, 34 (3) 565-579 10.1081/DMR-120005643
34. Clement, B.; Lopian, K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor Ximelagatran, an amidoxime and ester Prodrug Drug Metab. Dispos. 2003, 31 (5) 645-651 10.1124/dmd.31.5.645
35. Brandstetter, H.; Turk, D.; Hoeffken, H. W.; Grosse, D.; Stürzebecher, J.; Martin, P. D.; Edwards, B. F. P.; Bode, W. Refined 2·3ÅX-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA: A starting point for improving antithrombotics J. Mol. Biol. 1992, 226 (4) 1085-1099 10.1016/0022-2836(92)91054-S
36. Stürzebecher, J.; Vieweg, H.; Steinmetzer, T.; Schweinitz, A.; Stubbs, M. T.; Renatus, M.; Wikström, P. 3-Amidinophenylalanine-based inhibitors of urokinase Bioorg. Med. Chem. Lett. 1999, 9 (21) 3147-3152 10.1016/S0960-894X(99)00541-7
37. Hammami, M.; Ruhmann, E.; Maurer, E.; Heine, A.; Gutschow, M.; Klebe, G.; Steinmetzer, T. New 3-amidinophenylalanine-derived inhibitors of matriptase MedChemComm 2012, 3 (7) 807-813 10.1039/c2md20074k
38. Mueller, N. H.; Yon, C.; Ganesh, V. K.; Padmanabhan, R. Characterization of the West Nile virus protease substrate specificity and inhibitors Int. J. Biochem. Cell Biol. 2007, 39 (3) 606-614 10.1016/j.biocel.2006.10.025
39. Ekonomiuk, D.; Su, X.-C.; Ozawa, K.; Bodenreider, C.; Lim, S. P.; Otting, G.; Huang, D.; Caflisch, A. Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics J. Med. Chem. 2009, 52 (15) 4860-4868 10.1021/jm900448m
40. 50)/(non-hydrogen bonds) in kcal/mol according to Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Discovery Today 2004, 9 (10) 430-431 10.1016/S1359-6446(04)03069-7
41. Perola, E. An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs J. Med. Chem. 2010, 53 (7) 2986-2997 10.1021/jm100118x
42. Stürzebecher, J.; Prasa, D.; Hauptmann, J.; Vieweg, H.; Wikström, P. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine J. Med. Chem. 1997, 40 (19) 3091-3099 10.1021/jm960668h
43. Noble, C. G.; Seh, C. C.; Chao, A. T.; Shi, P. Y. Ligand-bound structures of the dengue virus protease reveal the active conformation J. Virol. 2012, 86 (1) 438-446 10.1128/JVI.06225-11
44. Bodenreider, C.; Beer, D.; Keller, T. H.; Sonntag, S.; Wen, D.; Yap, L.; Yau, Y. H.; Shochat, S. G.; Huang, D.; Zhou, T.; Caflisch, A.; Su, X.-C.; Ozawa, K.; Otting, G.; Vasudevan, S. G.; Lescar, J.; Lim, S. P. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease Anal. Biochem. 2009, 395 (2) 195-204 10.1016/j.ab.2009.08.013
45. Aleshin, A. E.; Shiryaev, S. A.; Strongin, A. Y.; Liddington, R. C. Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold Protein Sci. 2007, 16 (5) 795-806 10.1110/ps.072753207
46. Chen, X.; Murawski, A.; Patel, K.; Crespi, C.; Balimane, P. A novel design of artificial membrane for improving the PAMPA model Pharm. Res. 2008, 25 (7) 1511-1520 10.1007/s11095-007-9517-8
47. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The future of peptide-based drugs Chem. Biol. Drug Des. 2013, 81 (1) 136-147 10.1111/cbdd.12055
48. Yan, Z.; Caldwell, G. W. Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases Eur. J. Drug Metab. Pharmacokinet. 2003, 28 (3) 223-232 10.1007/BF03190489
49. Steuer, C.; Gege, C.; Fischl, W.; Heinonen, K. H.; Bartenschlager, R.; Klein, C. D. Synthesis and biological evaluation of α-ketoamides as inhibitors of the dengue virus protease with antiviral activity in cell-culture Bioorg. Med. Chem. 2011, 19 (13) 4067-4074 10.1016/j.bmc.2011.05.015
50. Steuer, C.; Heinonen, K. H.; Kattner, L.; Klein, C. D. Optimization of assay conditions for dengue virus protease: Effect of various polyols and nonionic detergents J. Biomol. Screening 2009, 14 (9) 1102-1108 10.1177/1087057109344115
51. Copeland, R. A. Enzymes: A Practical Introduction to Structure, Mechanism, And Data Analysis. 2nd ed.; John Wiley & Sons: New York, 2000; pp 305-317.
52. Nitsche, C.; Steuer, C.; Klein, C. D. Arylcyanoacrylamides as inhibitors of the dengue and West Nile virus proteases Bioorg. Med. Chem. 2011, 19 (24) 7318-7337 10.1016/j.bmc.2011.10.061
53. Nitsche, C.; Klein, C., Fluorimetric and HPLC-based dengue virus protease assays using a FRET substrate. In Antiviral Methods and Protocols; Gong, E. Y., Ed.; Humana Press: Totowa, NJ, 2013; Vol. 1030, pp 221-236.
54. Diamond, S. L. Thrombin 1536 HTS, Assay ID 1046. PubChem Open Chemistry Database; National Center for Biotechnology Information, U.S. National Library of Medicine: Bethesda, MD, 2008; http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=1046 (accessed May 26, 2015).
55. Cheng, Y.-C.; Prusoff, W. H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction Biochem. Pharmacol. 1973, 22 (23) 3099-3108 10.1016/0006-2952(73)90196-2
56. Copeland, R. A.; Lombardo, D.; Giannaras, J.; Decicco, C. P. Estimating KI values for tight binding inhibitors from dose-response plots Bioorg. Med. Chem. Lett. 1995, 5 (17) 1947-1952 10.1016/0960-894X(95)00330-V
57. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking1 J. Mol. Biol. 1997, 267 (3) 727-748 10.1006/jmbi.1996.0897
58. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-A visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25 (13) 1605-1612 10.1002/jcc.20084
59. Jernigan, F. E.; Sieracki, N. A.; Taylor, M. T.; Jenkins, A. S.; Engel, S. E.; Rowe, B. W.; Jové, F. A.; Yap, G. P. A.; Papish, E. T.; Ferrence, G. M. Sterically bulky tris(triazolyl)borate ligands as water-soluble analogues of tris(pyrazolyl)borate Inorg. Chem. 2007, 46 (2) 360-362 10.1021/ic061828a
60. Qiu, J.; Xu, B.; Huang, Z.; Pan, W.; Cao, P.; Liu, C.; Hao, X.; Song, B.; Liang, G. Synthesis and biological evaluation of Matijing-Su derivatives as potent anti-HBV agents Bioorg. Med. Chem. 2011, 19 (18) 5352-5360 10.1016/j.bmc.2011.08.001
61. Sassatelli, M.; Debiton, E.; Aboab, B.; Prudhomme, M.; Moreau, P. Synthesis and antiproliferative activities of indolin-2-one derivatives bearing amino acid moieties Eur. J. Med. Chem. 2006, 41 (6) 709-716 10.1016/j.ejmech.2006.03.021